TP53 and neoplasm: This is quite important, as the majority of SCC harbour mutations in the TP53 locus and TGFβ signalling can exert tumour‐prone or tumour‐suppressive effects depending on cell context as well as on the p53 status (Ikushima and Miyazono, 2010; Karlsson et al., 2017).